41 results
S-3ASR
AKRO
Akero Therapeutics Inc
10 May 24
Automatic shelf registration
4:57pm
), known as the SYMMETRY study;
the potential for another pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, to disrupt our … clinical trial of EFX in patients with compensated cirrhosis due to MASH (F4 fibrosis), known as the SYMMETRY study;
the potential for another pandemic
424B5
AKRO
Akero Therapeutics Inc
6 Mar 24
Prospectus supplement for primary offering
5:16pm
the ongoing COVID-19 pandemic;
our ability to submit information to regulatory authorities that supports initiation of our planned Phase 2b clinical trial … of EFX in cirrhotic NASH patients with F4 fibrosis, known as the SYMMETRY study, during the ongoing COVID-19 pandemic;
the potential for COVID-19
424B5
AKRO
Akero Therapeutics Inc
4 Mar 24
Prospectus supplement for primary offering
5:21pm
, known as the HARMONY study, including the ability to obtain data and maintain our expected timelines during the ongoing COVID-19 pandemic;
our ability … with F4 fibrosis, known as the SYMMETRY study, during the ongoing COVID-19 pandemic;
the potential for COVID-19 or other pandemic, epidemic or outbreak
8-K
sprqmjvrlq 7siftuz1
5 Jun 23
Results of Operations and Financial Condition
8:05am
424B5
ow61k8mxsf
17 May 23
Prospectus supplement for primary offering
4:45pm
8-K
b0on8 epb488d42q
29 Mar 23
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
5:20pm
424B5
by7jbsmz6uk1z6x3slf
15 Sep 22
Prospectus supplement for primary offering
5:16pm
424B5
b5t2s83e gwsvd
13 Sep 22
Prospectus supplement for primary offering
5:11pm
8-K
hi0n149cy wy002gsy
13 Sep 22
Regulation FD Disclosure
9:07am
424B5
p092kx9810
16 Jun 22
Prospectus supplement for primary offering
6:52am